MS

Permanent URI for this community

https://escholar.umt.edu.pk/handle/123456789/10120

Browse

Browsing MS by Author "ABDULLAH SHOAIB"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Tailoring of novel empagliflozin sodium glucose co-transporter 2 (sglt2) inhibitor, loaded zinc oxide nanoparticles for anti-diabetic activity
    (UMT, Lhr, 2022) ABDULLAH SHOAIB
    Diabetes was a serious health issue that can be a great risk factor related to numerous physical problems. A class of drugs “Gliflozin” especially Sodium glucose co.transporter 2 was inhibited by a novel drug, which is known as “empagliflozin”. It was used in the administration and cure of diabetes mellitus type-2, whereas Zinc Oxide nanoparticles were holding a great promise against diabetes. Here in this present research first of all Zinc Oxide nanoparticles were prepared by using the chemical coprecipitation method and tailored with the novel Empagliflozin drug by the surface physio-sorption method and percentage adsorption of the drug was evaluated by the HPLC method, as the 59.76 percent of the drug was tailored with the novel Empagliflozin drug. The tailored product was characterized by using the Ultraviolet visible, Fourier Transforms Infra-red, Energy Dispersive X. ray, X. ray Diffraction and Scanning Electron-Microscopy techniques. Ultravoilet-visible spectroscopy confirmed the generation of zinc oxide nanoparticles as the absorption spectra showed absorption maxima at 365 nm, Fourier transform Infrared showed the clear peaks at wavenumber between the 430 and 445 cm-1 ZnO stretching in the synthesized composite confirming the tailoring of the zinc oxide nanoparticles with the drug. The XRD analysis determination of the crystallite's size resulted in 12.35 nm. Scanning electron microscope showed mono-dispersion of nanoparticles and a sphere-like shape, with the average particle size of which is 17 nm whereas the elemental analysis with the energy dispersive X. ray exhibited sharp peaks of Zinc and Oxygen. Further, the adsorption capacities were studied by the adsorption isotherms and Freundlich isotherm model best fits and explained the data for physio-sorption study. The in-vitro anti-diabetic assays were preformed using the two major enzymes taking part in the human metabolism, α amylase as well as α-glucosidase, taking part in the human metabolism related to carbohydrates and it was studied that the composite showed the highest 81.72 and 92.77 percent inhibition of α-amylase and α-glucosidase at an absolute concentration of 1000 μg per ml with IC50 value of 3.06 and 72.44 μg per mL for of α-amylase and α glucosidase respectively exhibiting the maximum and improved antidiabetic activity.